RecruitingNCT07360158

BIO|MASTER.CorSky Family Post-market Study for the CorSky Family of ICDs

Post-market Study for the CorSky Family of ICDs

Sponsor

Biotronik SE & Co. KG

Enrollment

151 participants

Start Date

Jun 22, 2026

Study Type

OBSERVATIONAL

Conditions

Heart Failure Tachyarrhythmia

Summary

The CorSky family is BIOTRONIK´s new generation of ICDs. They are the successor devices of the current Acticor/Rivacor family and inherit all iShock/iShock\_BC (Ilivia Neo, Intica Neo) implant and programmer software features. The new features of CorSky Family are either true novel BIOTRONIK ICD features or mainly driven by unification with the Amvia pacemaker family (Amvia Edge, -Sky). The goal of the study is to confirm the safety and performance of the CorSky Family of ICDs and CRT-Ds.

Eligibility

Min Age: 18 YearsMax Age: 99 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called CorSky ICD or CRT-D for people with heart failure and tachyarrhythmia. The study is currently recruiting participants at 7 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICECorSky ICD or CRT-D

Subjects with an indication for an ICD or CRT-D device will be implanted with a CorSky device of the CorSky ICD family according to standard implantation procedures. Device programming will be done according to the medical needs of the subjects.